Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.
pleural effusion
pleural mesothelioma
predictive medicine
survival
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
16
04
2021
received:
09
02
2021
accepted:
16
04
2021
pubmed:
6
5
2021
medline:
5
1
2022
entrez:
5
5
2021
Statut:
ppublish
Résumé
Malignant pleural mesothelioma (MPM) is a rare, highly aggressive and deadly disease with a poor patient life expectancy. A few years ago, the main challenge was the histological diagnosis of this disease; at present, the search for the best therapeutic strategy is now a priority. However, an optimal therapeutic strategy is not yet clear, despite growing efforts in the treatment armamentarium and research, and at the era of tailored and individualized treatment, tools to predict patient survival are needed for therapeutic decision-making. Among them, the LENT scoring system was developed to predict prognosis in patients with malignant pleural effusion. The aim of this study was to assess the performance of the LENT score in predicting prognosis in patients with MPM. A retrospective observational study was conducted by analyzing the prospective collected databases of patients undergoing medical thoracoscopy in a single center with a final diagnosis of MPM confirmed by the MESOPATH National Reference Center. A total of 41 patients with MPM were studied. All patients underwent platinum-based chemotherapy combined with pemetrexed ± bevacizumab. No high-risk category patients were found using the LENT scoring system in this cohort. The median (range) LENT score at the time of medical thoracoscopy was 0 (0-3) and the median survival was 15.5 (2-54) months for the entire cohort. The median survival of low-risk and moderate-risk category patients was 21.4 months (2-54, 32 patients) and 6.7 months (2-19, nine patients), respectively. A total of 27 patients with MPM of epithelial subgroup had a median LENT score of 1 (0-2) with a 26 (2-54) months median survival. The median LENT score and median survival of nonepithelial mesothelioma patients (biphasic MPM subgroup, eight patients; sarcomatoid MPM subgroup, six patients) were 0 (0-3) and 11 (2-52) months, respectively. Applied to a homogenous cohort of MPM patients, the LENT score underestimated prognosis and was not useful per se for the management of this disease, as evidenced in the epithelial mesothelioma subgroup of patients in our study.
Sections du résumé
BACKGROUND
Malignant pleural mesothelioma (MPM) is a rare, highly aggressive and deadly disease with a poor patient life expectancy. A few years ago, the main challenge was the histological diagnosis of this disease; at present, the search for the best therapeutic strategy is now a priority. However, an optimal therapeutic strategy is not yet clear, despite growing efforts in the treatment armamentarium and research, and at the era of tailored and individualized treatment, tools to predict patient survival are needed for therapeutic decision-making. Among them, the LENT scoring system was developed to predict prognosis in patients with malignant pleural effusion. The aim of this study was to assess the performance of the LENT score in predicting prognosis in patients with MPM.
METHODS
A retrospective observational study was conducted by analyzing the prospective collected databases of patients undergoing medical thoracoscopy in a single center with a final diagnosis of MPM confirmed by the MESOPATH National Reference Center.
RESULTS
A total of 41 patients with MPM were studied. All patients underwent platinum-based chemotherapy combined with pemetrexed ± bevacizumab. No high-risk category patients were found using the LENT scoring system in this cohort. The median (range) LENT score at the time of medical thoracoscopy was 0 (0-3) and the median survival was 15.5 (2-54) months for the entire cohort. The median survival of low-risk and moderate-risk category patients was 21.4 months (2-54, 32 patients) and 6.7 months (2-19, nine patients), respectively. A total of 27 patients with MPM of epithelial subgroup had a median LENT score of 1 (0-2) with a 26 (2-54) months median survival. The median LENT score and median survival of nonepithelial mesothelioma patients (biphasic MPM subgroup, eight patients; sarcomatoid MPM subgroup, six patients) were 0 (0-3) and 11 (2-52) months, respectively.
CONCLUSIONS
Applied to a homogenous cohort of MPM patients, the LENT score underestimated prognosis and was not useful per se for the management of this disease, as evidenced in the epithelial mesothelioma subgroup of patients in our study.
Identifiants
pubmed: 33949775
doi: 10.1111/1759-7714.13987
pmc: PMC8169304
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1752-1756Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
J Thorac Oncol. 2015 Nov;10(11):1634-41
pubmed: 26317916
Lancet Oncol. 2018 Jul;19(7):930-939
pubmed: 29908990
Respiration. 2014;87(4):311-6
pubmed: 24457947
Ann Thorac Surg. 2017 Mar;103(3):962-966
pubmed: 27765170
J Thorac Oncol. 2014 Jun;9(6):856-64
pubmed: 24807157
PLoS One. 2015 Dec 14;10(12):e0145039
pubmed: 26660351
Transl Lung Cancer Res. 2020 Aug;9(4):1613-1616
pubmed: 32953534
J Thorac Oncol. 2012 Mar;7(3):587-94
pubmed: 22307011
J Clin Oncol. 1998 Jan;16(1):145-52
pubmed: 9440736
Semin Respir Crit Care Med. 2014 Dec;35(6):732-43
pubmed: 25463164
Thorac Cancer. 2021 Jun;12(11):1752-1756
pubmed: 33949775
J Thorac Oncol. 2016 Apr;11(4):573-82
pubmed: 26776867
Thorax. 2014 Dec;69(12):1098-104
pubmed: 25100651
BMC Pulm Med. 2015 Mar 28;15:29
pubmed: 25887349
J Thorac Oncol. 2018 Aug;13(8):1189-1203
pubmed: 29723687
Eur Respir J. 2020 Jun 11;55(6):
pubmed: 32451346
Jpn J Clin Oncol. 2015 Jun;45(6):562-8
pubmed: 25838292
J Thorac Oncol. 2016 Feb;11(2):249-55
pubmed: 26845118
J Surg Oncol. 2016 Apr;113(5):570-4
pubmed: 26751412
Front Oncol. 2020 Feb 18;10:126
pubmed: 32133285